3 ms·
My main issue here would be the fact the data is being sold to a private pharma company. The 'help' you are talking about might come at a huge cost, this simply
by vallode 7y ago
My main issue here would be the fact the data is being sold to a private pharma company. The 'help' you are talking about might come at a huge cost, this simply helps them develop ever more expensive drugs because they are the only ones holding the data.
- asdff 7y agoprivate pharma companies can already get access to confidential patient information during clinical trials. these protections are established and robust.